Hero

Royalty Pharma Donates $1,000,000 to Support Mount Sinai’s Covid-19 Patient Care and Clinical Research

Royalty Pharma Donates $1,000,000 to Support Mount Sinai’s Covid-19 Patient Care and Clinical Research

December 21, 2020

NEW YORK, NY, December 21, 2020 Royalty Pharma (Nasdaq: RPRX) today announced a charitable contribution by Royalty Pharma in the amount of $1,000,000 to Mount Sinai Health System. The funds will be used to support:

  • Mount Sinai’s Center for Post-COVID Care (CPCC) and Post-COVID Registry:  Royalty Pharma’s charitable contribution will study the long-term consequences of Covid-19 infection and provide advanced, innovative care for the ever-growing number of COVID-19 “long-haulers”.
  • Mount Sinai prospective study of individuals who already have antibodies to SARS-CoV-2 through infection or vaccination and monitor these antibodies over time, led by Florian Krammer, PhD, Professor of Vaccinology at the Icahn School of Medicine at Mount Sinai and Viviana Simon, PhD, MD, Professor of Microbiology/Medicine and member of the Global Health and Emerging Pathogens Institute at the Icahn School of Medicine at Mount Sinai

Over the course of the pandemic, the CPCC has cared for more than 20,000 patients with COVID-19, providing an invaluable, first-hand look at the many ways this virus attacks and affects the body. With an estimated 30-35% of COVID-19 survivors suffering from a variety of chronic conditions, the CPCC has proven essential in helping patients address the unique symptoms caused by this virus. The awareness that some of these symptoms are lingering led to the inception of the CPCC, one of the first such entities in the nation. The CPCC is a translational program wherein clinicians provide immediate care to patients in need, while scientists conduct cutting-edge research into the underlying biology of COVID-19. The CPCC has quickly become Mount Sinai’s centralized hub for a multitude of resources for patients who have recovered from acute infection of the virus.

Mount Sinai’s virologists—led by Florian Krammer, PhD—have been at the forefront of the COVID-19 crisis since the disease emerged in China last winter. Dr. Krammer and his team were the first in the nation to screen for viral antibodies by creating a novel, quantitative assay to pinpoint antibody levels (titers) for SARS-CoV-2 which are vital for vaccine development as well as in order to evaluate individual susceptibility to disease and population immunity.

“Mount Sinai has boldly faced the unprecedented challenge of the COVID-19 pandemic with dynamic ideas and limitless clinical and scientific efforts that have moved as quickly as the virus has spread in our communities. This generous gift makes it possible to continue the important work ahead,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean at the Icahn School of Medicine at Mount Sinai and President for Academic Affairs at Mount Sinai Health System. “We will not stop until this pandemic ends, until more lives are saved, until less people suffer from the debilitating effects of the disease caused by the virus and until we are equipped with the knowledge to prevent the next pandemic. This is our charge, and we will not rest until we have lessened the impact of this pandemic on our nation and the world.”

“The Mount Sinai Center for Post-COVID Care and COVID-19 Registry was established to treat and study the long-term consequences of Covid-19 infection,” said Juan Wisnivesky, MD, Professor of Medicine at Icahn School of Medicine and Co-Director of the CPCC. “Patients will be followed with yearly exams to assess the impact of Covid-19 on the cardiopulmonary system, renal function, immune function, neurological system, mental health and other organs. We are also creating a biorepository to perform analyses that can further unveil the biological impact of Covid-19 infection.”

“We are conducting studies that follow individuals who already have antibodies to SARS-CoV-2 through infection or vaccination and monitor these antibodies over time,” said Florian Krammer, PhD, “Based on

this data and potential breakthrough infections (reinfections) we are determining the level of antibodies that is needed to provide protection (correlate of protection).”

“Royalty Pharma is proud to partner with Mount Sinai’s Center for Post-COVID Care which provides important multi-specialty care and personalized treatment plans to patients still battling the aftereffects of this debilitating virus” said Pablo Legorreta, Founder & CEO of Royalty Pharma. “Dr. Kramer’s research and ability to determine the number of antibodies of an individual, rather than just their presence is a crucial differentiating factor as we continue to investigate prolonged immunity to COVID-19 and test the efficacy of many of the leading vaccine candidates. As COVID continues to strain communities, Royalty Pharma is committed to supporting academic research centers and teaching hospitals who are on the frontlines of fighting this pandemic.”

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko, Orkambi and Trikafta, and four development-stage product candidates. For more information, visit www.royaltypharma.com.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty by U.S. News & World Report.
For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.

Royalty Pharma plc’s Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. 

This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of Royalty Pharma’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. Royalty Pharma does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.  Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Royalty Pharma’s own internal estimates and research. While Royalty Pharma believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.  For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.
 

Royalty Pharma Investor Relations and Communications

+1 (212) 883-2295
ir@royaltypharma.com

Mount Sinai Health System Press Office
+ 1 (917) 837-8914
Lucia.Lee@mountsinai.org